Latest News and Press Releases

Finalized Dose Escalation/Dose Exploration Trial in 77 R/R AML PatientsFavorable safety with monotherapy responses across four dose levels with no DLT in mutationally diverse and difficult to treat...

Company Provides Comprehensive Clinical Update from Phase 1/2 TrialTuspetinib Continues to Deliver Single Agent Responses in r/r AML PatientsTuspetinib Safety and Efficacy Profile may Position Drug to...

SAN DIEGO and TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting...

– Initial modeling predicts up to 18-fold improvement in plasma steady-state exposure – – Supports exploration of continuous dosing of G3 formulation – – Lead clinical compound HM43239...

SAN DIEGO and TORONTO, May 25, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase...

Expands HM43239 dose cohort at 160 mg Headway with luxeptinib “G3” formulation in patients Conference call and webcast at 5:00 pm ET today SAN DIEGO and TORONTO, May 09, 2022 (GLOBE NEWSWIRE) --...

SAN DIEGO and TORONTO, May 02, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...

─ Appoints Philippe Ledru as Chief Commercial Officer ─ ─ Announces resignation of CFO/CBO Jotin Marango, MD, PhD ─ SAN DIEGO and TORONTO, April 07, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences...

HM43239 clinical update in AML after oral presentation at 2021 ASH Annual MeetingLuxeptinib clinical update in AML and B-cell cancers SAN DIEGO and TORONTO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Aptose...

- Conference call and webcast at 5:00 pm EDT today - - Luxeptinib Phase 1a/b studies in AML and B cell malignancies fully enrolled at 750 mg dose - - APTO-253 Phase 1a/b study in AML / MDS treating...